Thrombosis Research
Volume 125 , Pages S16-S18 , April 2010

Platelet binding and activity of recombinant factor VIIa

  • Maureane Hoffman

      Affiliations

    • Duke University, Durham Veterans Affairs, Durham and Chapel Hill, North Carolina, USA
    • Corresponding Author InformationCorresponding author. Pathology & Laboratory Medicine Service, Durham VA Medical Center, 508 Fulton St, Durham, NC 27705, USA. Tel.: +1 919 286 0411x6494, +1 919 684 3300; fax: +1 919 286 6818.
    • ,
  • Dougald M. Monroe

      Affiliations

    • University of North Carolina Medical Centers, Durham and Chapel Hill, North Carolina, USA

References 

  1. Hedner U, Kisiel W. Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. J Clin Invest. 1983;71:1836–1841
  2. Osterud B. How to measure factor VII and factor VII activation. Haemostasis. 1983;13:161–168
  3. Bom VJ, Bertina RM. The contributions of Ca2+, phospholipids and tissue-factor apoprotein to the activation of human blood-coagulation factor X by activated factor VII. Biochem J. 1990;265:327–336
  4. Rao LV, Rapaport SI. Factor VIIa-catalyzed activation of factor X independent of tissue factor: its possible significance for control of hemophilic bleeding by infused factor VIIa. Blood. 1990;75:1069–1073
  5. Rao LV, Rapaport SI. Cells and the activation of factor VII. Haemostasis. 1996;26(Suppl 1):1–5
  6. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol. 1997;99:542–547
  7. Hoffman M, Monroe DM. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Semin Hematol. 2001;38:6–9
  8. van't Veer C, Golden NJ, Mann KG. Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa. Blood. 2000;95:1330–1335
  9. Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Haemost. 2001;85:958–965
  10. Monroe DM, Hoffman M. What does it take to make the perfect clot?. Arterioscler Thromb Vasc Biol. 2006;26:41–48
  11. Roberts HR, Monroe DM, Hoffman M. Safety profile of recombinant factor VIIa. Semin Hematol. 2004;41:101–108
  12. Seremetis S. Dose optimization of recombinant factor VIIa in the treatment of acute bleeding in haemophilia-associated inhibitors. Blood Coagul Fibrinolysis. 2003;14(Suppl 1):S29–S30
  13. Tranholm M, Kristensen K, Kristensen AT, Pyke C, Rojkjaer R, Persson E. Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A. Blood. 2003;102:3615–3620
  14. Weeterings C, Lisman T, de Groot PG. Tissue factor-independent effects of recombinant factor VIIa on hemostasis. Semin Hematol. 2008;45:S12–S15
  15. Weeterings Cees, de Groot Philip G, Adelmeijer Jelle, Lisman Ton. The glycoprotein Ib-IX-V complex contributes to tissue factor-independent thrombin generation by recombinant factor VIIa on the activated platelet surface. Blood. Oct 2008;112:3227–3233
  16. Persson E, Kjalke M, Olsen OH. Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity. Proc Natl Acad Sci U S A. 2001;98:13583–13588
  17. Hope MJ, Bally MB, Webb G, Cullis PR. Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochemica et Biophysica Acta. 1985;812:55–65
  18. Ohkubo YZ, Tajkhorshid E. Distinct structural and adhesive roles of Ca2+ in membrane binding of blood coagulation factors. Structure. 2008;16:72–81

PII: S0049-3848(10)00078-2

doi: 10.1016/j.thromres.2010.01.025

Thrombosis Research
Volume 125 , Pages S16-S18 , April 2010

Article Tools

* Image Usage & Resolution